Atopic dermatitis drug Ebglyss to enter Korea next year
By Whang, byung-woo | translator Alice Kang
24.10.31 05:00:57
가나다라
0
Ebglyss, the 3rd biologic for atopic dermatitis is set to be released to market without reimbursement
Other competitors suffer reimbursement hurdles…hopes are on HIRA’s approval of the JAKi-biologic switching administration approval
Lilly applies for Ebglyss’s reimbursement upon its approval, when it enters the market will serve as the key to its competition
The atopic dermatitis drug Ebglyss (lebrikizumab), which is set to soon be released in Korea, has added competitivity by securing rationale for switching between biologics.
The company plans to receive reimbursement after launching the drug without reimbursement early next year.
▲Pic of Ebglyss
At the recent Fall Clinical Dermatology conference that was held in the U.S., Lilly presented results from the ADapt Phase IIIb study, which confirmed the effectiveness of Ebglyss in patients with moderate-to-severe atopic dermatitis who were previously treated with Dupixent (dupilumab). Patients in the ADapt study were those who discontinued Dupixent due to insufficient response, intolerance, ad
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)